Neccessasity of Bio-imaging Hybrid Approaches Accelerating Drug Discovery Process (Mini-Review)
暂无分享,去创建一个
[1] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[2] Shu-Gui Huang,et al. Development of a High Throughput Screening Assay for Mitochondrial Membrane Potential in Living Cells , 2002, Journal of biomolecular screening.
[3] Kai Huang,et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..
[4] D. Rognan,et al. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.
[5] A. Good,et al. High-throughput and virtual screening: core lead discovery technologies move towards integration. , 2000, Drug discovery today.
[6] J. Medina-Franco,et al. Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context , 2014, ChemMedChem.
[7] Ajay N. Jain. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..
[8] J. Pin,et al. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.
[9] B. Neagle,et al. FLIPR: A New Instrument for Accurate, High Throughput Optical Screening , 1996 .
[10] R. Aggeler,et al. Tools to Measure Cell Health and Cytotoxicity Using High Content Imaging and Analysis. , 2018, Methods in molecular biology.
[11] P. Liberali,et al. Single-cell and multivariate approaches in genetic perturbation screens , 2014, Nature Reviews Genetics.
[12] H. Groen,et al. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. , 2006, Lung cancer.
[13] João Rodrigues,et al. Why and how have drug discovery strategies in pharma changed? What are the new mindsets? , 2016, Drug discovery today.
[14] Yoshitomo Hamuro,et al. Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.
[15] Teresa Kaserer,et al. Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2 , 2015, European journal of medicinal chemistry.
[16] Obdulia Rabal,et al. An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. , 2010, Molecular bioSystems.
[17] József Nagy,et al. Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.
[18] E. Lionta,et al. Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.
[19] Ruben Abagyan,et al. Novel cGMP efflux inhibitors identified by virtual ligand screening (VLS) and confirmed by experimental studies. , 2012, Journal of medicinal chemistry.
[20] M. Raichle,et al. Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.
[21] W. Drevets,et al. The Subgenual Anterior Cingulate Cortex in Mood Disorders , 2008, CNS Spectrums.
[22] Gang Liu,et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.
[23] H. Remmer,et al. The role of the liver in drug metabolism , 1970 .
[24] Campbell McInnes,et al. Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.
[25] J. Wendoloski,et al. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.
[26] Yasuyoshi Watanabe,et al. [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.
[27] F. Totzke,et al. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization. , 2009, Bioorganic & medicinal chemistry.
[28] S. Perry,et al. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. , 2011, BioTechniques.
[29] E. Kantrowitz,et al. A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. , 2009, Bioorganic & medicinal chemistry.
[30] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[31] Wolfgang Link,et al. High content screening: seeing is believing. , 2010, Trends in biotechnology.
[32] Thomas Blaschke,et al. The rise of deep learning in drug discovery. , 2018, Drug discovery today.
[33] R. Weissleder,et al. Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[34] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[35] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[36] S. Danti,et al. Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study , 2015, Journal of functional biomaterials.
[37] Kiran Boppana,et al. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. , 2009, European journal of medicinal chemistry.
[38] Nadine H. Elowe,et al. Experimental Screening of Dihydrofolate Reductase Yields a “Test Set” of 50,000 Small Molecules for a Computational Data-Mining and Docking Competition , 2005, Journal of biomolecular screening.
[39] Sissades Tongsima,et al. Pre-docking filter for protein and ligand 3D structures , 2008, Bioinformation.
[40] Vladimir Poroikov,et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource , 2014, Chemistry of Heterocyclic Compounds.
[41] D. Schuster,et al. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. , 2016, European journal of medicinal chemistry.
[42] Jeffrey W. Peng,et al. Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.
[43] Robert Nadon,et al. Systematic error detection in experimental high-throughput screening , 2011, BMC Bioinformatics.
[44] Emilio Bombardieri,et al. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[45] Jean-Pierre Gotteland,et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.
[46] Wei-liang Zhu,et al. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets , 2009, Acta Pharmacologica Sinica.
[47] William Thomsen,et al. Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.